Year-Over-Year Revenue Growth
IRIDEX achieved a strong year-over-year revenue growth of 8% for the third quarter of 2025, reaching $12.5 million in revenue.
Reduction in Operating Expenses
Operating expenses were reduced by 12% in the third quarter of 2025 compared to the same period in 2024, and by 25% for the nine months ending September 27, 2025.
Improved Adjusted EBITDA
Adjusted EBITDA improved by $1.3 million compared to the prior year period, with a non-GAAP adjusted EBITDA loss of $131,000 for Q3 2025.
Growth in Glaucoma Product Group
The Cyclo G6 glaucoma product group revenue grew by 13% year-over-year, with system sales increasing to 30 units from 26 in the prior year period.
Positive Projections for Cash Flow
IRIDEX is on track to achieve positive cash flows in the fourth quarter of 2025 and sustained cash flow positivity in 2026.